Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a price target of $34.
August 08, 2023 | 5:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Day One Biopharmaceutical and maintained a price target of $34.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $34 price target indicates a positive outlook for Day One Biopharmaceutical. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100